Tirzepatide ���子背景与靶点 — Worked Examples

By Editorial Desk · published 2026-07-26 · last reviewed 2026-08-01 · Wiki

deamidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tirzepatide 分子背景与靶点

该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Analytical Characterization and Storage

Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.

Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.

Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.

Tirzepatide at a glance

Handling, Storage, and Analytical Methods

Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.

Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.

Related pages on this site

• Scalable comparison
• Technical trends
• Smart archive
• Focused checklist
• Technical checklist
• Sustainable collection
• Proven index
• Seasonal digest

Background and Dual Receptor Pharmacology

Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.

Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.

Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.

Analytical Methods And Storage Stability

The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.

Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.

Analytical Characterization and Stability

Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.

Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.

Supporting material

Activation of presynaptic dopamine autoreceptors by dihydroergocriptine leads to reduced dopamine receptor turnover and indirect antioxidant effects. In particular, further activation of intracellular kinase systems due to dopamine agonists are hypothesized to lead to antiapoptotic effects that also help in halting and slowing the disease progression. This may also contribute to prevention of development of motor fluctuations, though more research is needed. Modern agonists like dihydroergocryptine typically cost two to three times more than levodopa therapy. More health economics assessments may be needed to determine whether the initial increased costs of the agonists are offset by less patients needing surgery in later stages of the disease.

=== Bioactive content === In addition to nutritional benefits, breastmilk also provides enzymes, antibodies, and other substances that support the infant's growth and development. The bioactive makeup of breastmilk also changes based on the needs of the infant; for example, when an infant is recovering from an upper respiratory infection, local signaling allows for increased passage of immune cells and proteins to aid the infant's immune system. Produced during pregnancy and the first after childbirth, colostrum is easy to digest and has laxative properties that help the infant to pass early stools. This aids in the excretion of excess bilirubin, which helps to prevent jaundice. Colostrum also helps to seal the infants gastrointestinal tract from foreign substances and germs, which may sensitize the baby to foods that the mother has eaten and decrease the risk of diarrheal illness. Although the baby has received some antibodies (IgG) through the placenta, colostrum contains a substance which is new to the newborn, secretory immunoglobulin A (IgA). IgA works to attack germs in the mucous membranes of the throat, lungs, and intestines, which are most likely to come under attack from germs. Additionally, colostrum and mature breast milk contain many antioxidant and anti-inflammatory enzymes and proteins that decrease the risk of gastrointestinal allergies to food, respiratory allergies to air particles like pollen, and other atopic diseases, such as asthma and eczema.

The GARS1 gene encodes the enzyme glycyl-tRNA synthetase (GlyRS), which belongs to the class II group of aminoacyl-tRNA synthetases. This enzyme is essential in the process of protein synthesis, facilitating the bonding of the amino acid glycine to its corresponding transfer RNA (tRNA). Through this process, GlyRS ensures the accurate incorporation of glycine during translation, making it essential for proper protein production. Many different mutations have been found in CMT2D patients, and how mutations in GARS1 cause CMT2D remains unclear. However, mutant glycyl-tRNA synthetase (GlyRS) is thought to interfere with transmembrane receptors, causing motor disease, and that mutations in the gene could disrupt the ability of GlyRS to interact with its cognate RNA, disrupting protein production. The GARS1 mutations present in CMT2D cause a deficient amount of glycyl-tRNA in cells, preventing the elongation phase of protein synthesis. Elongation is a key step in protein production, so when a deficiency of glycyl-tRNA exists, protein synthesis is unable to continue at glycine sites. GARS1 mutations also stall initiation of translation due to a stress response that is induced by glycine addition failure. By stalling elongation and initiation of translation, CMT2D mutations in GARS1 cause translational repression, meaning that overall translation is inhibited. GARS1-associated axonal neuropathy is a progressive condition that deteriorates over time.

Sources: en.wikipedia.org

Notes from published material

Keven Verdun Thacker, Chief Executive Officer, the Lighting Association. For services to Domestic Energy Efficiency. Noel Thatcher. For services to Athletics for Disabled People. Marshall Thew, . For charitable and community services in Wirral. Gwendoline Marian Thomas, Executive Officer, Department of Social Security. John Edwin Thomas, Leading Firefighter, West Midlands Fire Service. For services to the Fire Service. Marina Ann Thomas, School Crossing Patrol, Newton Abbot, Devon County Council. For services to Road Safety. Martyn Edmund Thomas, Managing Director, Sulzer (UK) Pumps Ltd. For services to the Engineering Industry. Kenneth Charles Thompson, Pay Band 8, the Employment Service, Department for Education and Employment. Neil Dennis Thompson, Sub-Officer (Retained), Nottinghamshire Fire and Rescue Service. For services to the Fire Service. Douglas Albert Till. For services to Training in Worcester. Anthony Richard Shaw Timmis. For services to the Building Industry and to the community in Yeovil, Somerset. Dawn Pauline Toomey, Higher Executive Officer, Office for National Statistics. John Joseph Tovey. For services to Tourism in Cumbria. Stephanie Catherine Townsend, Executive Officer, Ministry of Agriculture, Fisheries and Food. Rita Trevennen. For services to the Citizens' Advice Bureau in Penzance, Cornwall. Arthur George Cecil Trollope. For services to Conservation and to the community in London. Doris A. P. Troup, Member, Parkinson's Disease Society, Aberdeen. For services to Health Care. Brian Tuckley, Safety Officer, Institute of Food Research.

=== Aromatase inhibitors === Aromatase inhibitors are an important class of drugs used for the treatment of breast cancer in postmenopausal women. At menopause, estrogen production in the ovaries ceases, but other tissues continue to produce estrogen through the action of the enzyme aromatase on androgens produced by the adrenal glands. When the action of aromatase is blocked, estrogen levels in post-menopausal women can drop to extremely low levels, causing growth arrest and/or apoptosis of hormone-responsive cancer cells.

From its origin in 1922 until 1939, WOSM did not have its own emblem. In 1939, its director, J. S. Wilson, introduced an international Scout badge: a silver fleur-de-lis on a purple background containing the five continent names in silver, framed between two concentric circles. Wearing of the badge was confined to WOSM committee members and bureau staff and their past members. The design became WOSM's logo and a purple flag containing the design followed, the flying of which was restricted to WOSM international Scout gatherings.

=== Transport Reaction === The generalized transport reaction catalyzed by members of the CPA2 family is:M+ (in) + nH+ (out) ⇌ M+ (out) + nH+ (in).(The carrier-mediated mode)Some members may also catalyze:M+ (in) ⇌ M+ (out).(The channel-mediated mode)

Sources: en.wikipedia.org

Further detail

== F == fab immunoglobulin - facilitated diffusion - factor VIII - FADH - FADH2 - Fat - Fatty acid - fc immunoglobulin - fc receptor - feedback inhibition - fermentation - fetal protein - fibroblast growth factor - fibroblast growth factor receptor - fibronectin - Fick's law of diffusion - Filtration - fitness (biology) - fitness landscape - flagellum - flavin adenine dinucleotide - flavine - flavoprotein - fluid mosaic model - fms gene - Formaldehyde - fos gene - free energy - freezing point - FSH receptor - functional group - fungal protein - fungi - fusion oncogene protein

=== Historic regulations === Because it was recognized that coffee contained some compound that acted as a stimulant, first coffee and later also caffeine has sometimes been subject to regulation. For example, in the 16th century Islamists in Mecca and in the Ottoman Empire made coffee illegal for some classes. Charles II of England tried to ban it in 1676, Frederick II of Prussia banned it in 1777, and coffee was banned in Sweden at various times between 1756 and 1823. In 1911, caffeine became the focus of one of the earliest documented health scares, when the US government seized 40 barrels and 20 kegs of Coca-Cola syrup in Chattanooga, Tennessee, alleging the caffeine in its drink was "injurious to health". Although the Supreme Court later ruled in favor of Coca-Cola in United States v. Forty Barrels and Twenty Kegs of Coca-Cola, two bills were introduced to the US House of Representatives in 1912 to amend the Pure Food and Drug Act, adding caffeine to the list of "habit-forming" and "deleterious" substances, which must be listed on a product's label.

==== Intranasal ==== The intranasal route for naloxone was studied as early as 2001 by Paramedics in Denver, Colorado to test the route's feasibility as an alternative to IV administration. In a small sample size over the course of one month, 91% of patients who responded to naloxone by any route responded to IN naloxone without additional IV naloxone being administered. Narcan nasal spray was approved in the US in 2015 and is the first FDA-approved nasal spray for emergency treatment of suspected overdose. It was developed in a partnership between LightLake Therapeutics and the National Institute on Drug Abuse. The approval process was fast-tracked. A generic version of the nasal spray was approved in the United States in 2019, though did not come to market until 2021. In 2021, the FDA approved Kloxxado, an 8 mg dose of intranasal naloxone developed by Hikma Pharmaceuticals. Citing the frequent need for multiple 4 mg doses of Narcan to successfully reverse overdose, packs of Kloxxado Nasal Spray contain two pre-packaged nasal spray devices, each containing 8 mg of naloxone. However, a wedge device (nasal atomizer) can also be attached to a syringe that may also be used to create a mist to deliver the drug to the nasal mucosa. This is useful near facilities where many overdoses occur that already stock injectors.

=== Spectrum of activity === Caspofungin has been effective in treating fungal infections caused by Aspergillus and Candida species. It is a member of the echinocandin family, a new class of antifungal agents with broad spectrum of activity against all Candida species. In comparison to treatment with either fluconazole or amphotericin B, all three drugs in this class have been demonstrated to be highly effective or superior in well-defined clinical settings including invasive Candida infections, Candida oesophagitis and candidaemia. Higher minimum inhibitory concentration (MIC) of these agents has been observed against C. parapsilosis and C. guilliermondii. In a few patients with infections caused by Candida albicans, mutants with reduced sensitivity to caspofungin have been noticed, but is currently still rare. The mechanism is probably a point mutation in the (1→3)-β-D-glucan synthase gene. There are no data regarding development of resistance in other fungi than C. albicans. The following summarizes MIC susceptibility for a few medically significant organisms.

== Therapeutic effects == Serotonin, given orally at a dose of 100 mg, produced effects in humans including blood pressure changes, abdominal cramps, muscle aches, and a feeling of sedation. In contrast to psychedelic drugs like LSD, no hallucinogenic effects were reported. In other studies, serotonin, at low intravenous doses of 2 to 6 mg, had no effects on electroencephalogram (EEG) readings in humans. In accordance with the preceding findings, it has been stated that administration of serotonin in humans produces no psychoactive effects that cannot be attributed to anxiety by its profound peripheral adverse effects including circulatory disturbance, other autonomic effects, and vomiting. Intracerebroventricular injection of serotonin has been studied in patients with severe psychiatric conditions, but little information about its psychoactive effects is provided. It is thought that exogenous serotonin is too hydrophilic to cross the blood–brain barrier and has too poor of metabolic stability due to rapid metabolism by monoamine oxidase (MAO) such that it cannot produce drug-like central effects in humans with peripheral administration. However, close analogues of serotonin that are more lipophilic and metabolically stable, like bufotenin (N,N-dimethylserotonin), 5-MeO-DMT (N,N,O-trimethylserotonin), and 5-MeO-AMT (α,O-dimethylserotonin), among many others, are active and produce pronounced centrally mediated effects in humans.

Sources: en.wikipedia.org

Frequently asked questions